CEA (carcinoembryonic antigen) and CYFRA (cytokeratin 19 fragment) are elevated in sera in a subset of lung cancer patients, and are clinically applied to monitor the disease status and evaluate the response to treatments. Here, CEACAM5 is linked to lung cancer.